{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T15:52:06Z","timestamp":1790351526020,"version":"4.1.0"},"reference-count":27,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2012,11,5]],"date-time":"2012-11-05T00:00:00Z","timestamp":1352073600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100000097","name":"National Center for Research Resources","doi-asserted-by":"crossref","award":["3UL1RR024156-04S4"],"award-info":[{"award-number":["3UL1RR024156-04S4"]}],"id":[{"id":"10.13039\/100000097","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000097","name":"National Center for Research Resources","doi-asserted-by":"crossref","award":["UL1RR025750"],"award-info":[{"award-number":["UL1RR025750"]}],"id":[{"id":"10.13039\/100000097","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000097","name":"National Center for Research Resources","doi-asserted-by":"crossref","award":["KL2RR025749"],"award-info":[{"award-number":["KL2RR025749"]}],"id":[{"id":"10.13039\/100000097","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000097","name":"National Center for Research Resources","doi-asserted-by":"crossref","award":["TL1RR025748"],"award-info":[{"award-number":["TL1RR025748"]}],"id":[{"id":"10.13039\/100000097","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pediatric Blood &amp; Cancer"],"published-print":{"date-parts":[[2013,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Hydroxyurea (HU) is highly effective treatment for sickle cell disease (SCD). While pediatric use of HU is accepted clinical practice, barriers to use may impede its potential benefit.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Procedure<\/jats:title>\n                    <jats:p>A survey of parents of children ages 5\u201317 years with SCD was performed across five institutions to assess factors associated with HU use.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of the 173 parent responses, 65 (38%) had children currently taking HU. Among parents of children not taking HU, the most commonly cited reasons were that their hematology provider had not offered it, their child was not sufficiently symptomatic and concerns about potential side effects. Even parents of HU users reported widespread concern about effectiveness, long\u2010term safety, and off\u2010label use. In bivariate analyses, children's ages, parental demographics such as education level, or travel time to their hematology provider were not correlated with HU use. Bivariate analysis and multivariate logistic regression revealed three significant factors associated with current HU use: better parental knowledge about its major therapeutic effects (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001), sickle genotype (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.005), and institution of clinical care (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.04).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Pervasive concerns about HU safety exist, even among parents of current users. Varying knowledge among parents appears to be independent of their demographics, and is associated with HU use. Inter\u2010institutional variability in parental knowledge and drug uptake highlights potentially potent site\u2010specific influences on likelihood of HU use. Overall, these survey data underscore the need for strategies to bolster parental understanding about benefits of HU and address concerns about its safety. Pediatr Blood Cancer 2013; 60: 653\u2013658. \u00a9 2012 Wiley Periodicals, Inc.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/pbc.24381","type":"journal-article","created":{"date-parts":[[2012,11,5]],"date-time":"2012-11-05T12:41:49Z","timestamp":1352119309000},"page":"653-658","source":"Crossref","is-referenced-by-count":62,"title":["Parental and other factors associated with hydroxyurea use for pediatric sickle cell disease"],"prefix":"10.1002","volume":"60","author":[{"given":"Suzette O.","family":"Oyeku","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Catherine","family":"Driscoll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hillel W.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Trachtman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farzana","family":"Pashankar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig","family":"Mullen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia J.","family":"Giardina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nerissa","family":"Velazco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew D.","family":"Racine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy S.","family":"Green","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,11,5]]},"reference":[{"key":"e_1_2_6_2_2","unstructured":"National Institutes of Health. National Heart Lung and Blood Disease Institute and Division of Blood Diseases and Resources.The management of sickle cell disease. NIH Publication (No. 02\u20102117) 4th edition. Bethesda MD; 2002."},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199505183322001"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.289.13.1645"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1097\/MPH.0b013e3182114c54"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1097\/MOH.0b013e32834521dd"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.21968"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60355-3"},{"key":"e_1_2_6_9_2","first-page":"1550","article-title":"Safety of hydroxyurea in children with sickle cell anemia: Results of the HUG\u2010KIDS study, a phase I\/II trial","volume":"94","author":"Kinney TR","year":"1999","journal-title":"Blood"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1097\/00043426-200007000-00009"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-07-2475"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2009.11.002"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-04-146852"},{"key":"e_1_2_6_14_2","unstructured":"National Institutes of Health National Heart Lung and Blood Institute.Draft recommendations on the use of hydroxyurea therapy in sickle cell disease; November 17 2010."},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.22822"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-148-12-200806170-00220"},{"key":"e_1_2_6_17_2","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1177\/0145721710385579","article-title":"Facilitators and barriers to self\u2010management of type 2 diabetes among urban African American adults: Focus group findings","volume":"36","author":"Chlebowy DO","journal-title":"Diabetes Educ"},{"key":"e_1_2_6_18_2","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1097\/QAI.0b013e3181c57dbc","article-title":"Conspiracy beliefs about HIV are related to antiretroviral treatment nonadherence among African American men with HIV","volume":"53","author":"Bogart LM","journal-title":"J Acquir Immune Defic Syndr"},{"key":"e_1_2_6_19_2","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1089\/apc.2009.0288","article-title":"Trust in physicians and racial disparities in HIV care","volume":"24","author":"Saha S","journal-title":"AIDS Patient Care STDS"},{"key":"e_1_2_6_20_2","first-page":"3","article-title":"Barriers and facilitators of medication adherence in hypertensive African Americans: A qualitative study","volume":"14","author":"Ogedegbe G","year":"2004","journal-title":"Ethn Dis"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1207\/s15327558ijbm0603_2"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.21883"},{"key":"e_1_2_6_23_2","first-page":"1","article-title":"Hydroxyurea for the treatment of sickle cell disease","author":"Segal JB","year":"2008","journal-title":"Evid Rep Technol Assess (Full Rep)"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0027-9684(15)31419-X"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.20353"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.21749"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.21565"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.23221"}],"container-title":["Pediatric Blood &amp; Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpbc.24381","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpbc.24381","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pbc.24381","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,18]],"date-time":"2023-10-18T14:35:48Z","timestamp":1697639748000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pbc.24381"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11,5]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,4]]}},"alternative-id":["10.1002\/pbc.24381"],"URL":"https:\/\/doi.org\/10.1002\/pbc.24381","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.717962602.793464543","asserted-by":"object"}]},"ISSN":["1545-5009","1545-5017"],"issn-type":[{"value":"1545-5009","type":"print"},{"value":"1545-5017","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,11,5]]}}}